Comparison of the effects of ipratropium/salbutamol drugs combination with another drug, called glycopyrronium, all given by nebulization, in patients suffering from the disease called, chronic obstructive pulmonary disease, and are now very sick and on ventilator.
- Conditions
- Health Condition 1: J440- Chronic obstructive pulmonary disease with acute lower respiratory infection
- Registration Number
- CTRI/2022/11/047216
- Lead Sponsor
- Dr Ram Manohar Lohia Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
1. Those patients whose next of kin consents to participation in the study
2. Age >18 years, <75yrs, of either sex.
3. Known case of COPD who were intubated and mechanically ventilated.
1.Patient’s kin’s refusal to give consent
2.Patient with heart diseases like coronary artery disease-confirmed or suspected, and valvular disease
3.Patients with tachyarrhythmia
4.Those patients who had pre-existing thick or inspissated sputum.
5.Patients on any heart rate controlling drug, like beta blockers, calcium channel blockers, amiodarone or ivabradine.
6.Patients with a diagnosis of pneumonia, pulmonary oedema, refractory hypoxaemia, pneumothorax, haemodynamic instability.
7.Patients who have known sensitivity to Glycopyrrolate, salbutamol or ipratropium.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness in causing bronchodilation is by the End-inspiratory static compliance (Cstat), minimum (Rint) and maximum (Rrs) resistance of the respiratory system.and duration by the time the Rint remains less than 85% of baseline value. <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: Data will be collected at 15, 30, 60 minutes as well as at 2, 3, 4, 6, 8, 10 and 12 hours after each nebulisation.
- Secondary Outcome Measures
Name Time Method To examine the incidence of any side effect attributable to nebulized, long acting muscarinic antagonist, glycopyrronium in critically ill mechanically ventilated patients of COPD.Timepoint: Data will be collected at 15, 30, 60 minutes as well as at 2, 3, 4, 6, 8, 10 and 12 hours after each nebulisation.